ethyl icosapentate
ethyl (all cis)-5,8,11,14,17-icosapentaenoate
Identification
| Name | ethyl icosapentate |
| IUPAC | ethyl (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate |
| CAS Number | 73310-10-8 |
| FDA UNII | 6GC8A4PAYH |
| Molecular Formula | C22 H34 O2 |
| Molecular Weight | 330.51138000 |
Regulatory
Physical Properties
| Assay | 95.00 to 100.00 |
| Food Chemicals Codex Listed | No |
| Soluble in | water, 0.0003466 mg/L @ 25 °C (est) |
No sensory data available
Safety Information
| Oral/Parenteral Toxicity | intraperitoneal-mouse LD50 > 20000 mg/kg |
| Dermal Toxicity | subcutaneous-mouse LD50 > 20000 mg/kg |
| Inhalation Toxicity | Not determined |
GHS Classification
['GHS Classification in accordance with 29 CFR 1910 (OSHA HCS)', 'GHS Label elements, including precautionary statements']
Safety in Use
| Category | natural substances and extractives |
| Recommendation for ethyl icosapentate usage levels up to | not for fragrance use. |
| Recommendation for ethyl icosapentate flavor usage levels up to | not for flavor use. |
No supplier data available
Potential Uses
Natural Occurrence
Synonyms
eicosapentaenoic acid ethyl ester
ethyl (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate
ethyl (all cis)-5,8,11,14,17-icosapentaenoate
ethyl eicosapentaenoic acid
PubMed:
Prescription omega-3 fatty acid products containing highly purified eicosapentaenoic acid (EPA).
PubMed:
The NMatrix, a new method of presenting statistics, displays the characteristics of medicines with similar effects used in the treatment of lumbar spinal stenosis concisely and clearly, facilitating the selection of appropriate medications.
PubMed:
Aspirin- and clopidogrel-associated bleeding complications: data mining of the public version of the FDA adverse event reporting system, AERS.
PubMed:
Successful treatment of lipoprotein glomerulopathy in a daughter and a mother using niceritrol.
PubMed:
[A case of type 2 diabetes mellitus associated with familial hypercholesterolemia confirming the improvement of blood glucose control by colestimide].
PubMed:
[A 50-year history of new drugs in Japan-the development and trends of hemostatics and antithrombotic drugs].
PubMed:
Ethyl icosapentate (omega-3 fatty acid) causes accumulation of lipids in skeletal muscle but suppresses insulin resistance in OLETF rats. Otsuka Long-Evans Tokushima Fatty.
PubMed:
Resolution of typical lipoprotein glomerulopathy by intensive lipid-lowering therapy.
PubMed:
Lipid-lowering therapy and coagulation/fibrinolysis parameters in patients on peritoneal dialysis.
PubMed:
[A 50-year history of new drugs in Japan: the developments and trends of antihyperlipidemic drugs].
PubMed:
Effect of ethyl icosapentate on urinary calcium and oxalate excretion.
PubMed:
Eicosapentaenoic acid effect on hyperlipidemia in menopausal Japanese women. The Niigata Epadel Study Group.
PubMed:
Eicosapentaenoic acid stimulates nitric oxide production and decreases cardiac noradrenaline in diabetic rats.
PubMed:
[Anti-hyperlipidemic drug].
PubMed:
Evaluation of ethyl icosapentate in the treatment of hypercholesterolemia in kidney transplant recipients.
PubMed:
Comparative studies of an orally-active factor Xa inhibitor, YM-60828, with other antithrombotic agents in a rat model of arterial thrombosis.
PubMed:
[Blood rheological study in rats with fatty liver--with special reference to effects of ethyl icosapentate].
PubMed:
Effect of ethyl icosapentate on urinary calcium excretion in calcium oxalate stone formers.
PubMed:
Chemical stability of ethyl icosapentate against autoxidation. II. Effect of photoirradiation on oxidation kinetics.
PubMed:
[Large scale multicenter cooperative study for cardiovascular therapy (Japan Multicenter Investigation for Cardiovascular Drugs/Therapies, J-MIC)--results and perspectives].
PubMed:
Chemical stability of ethyl icosapentate against autoxidation. I. Effect of temperature on oxidation kinetics.